Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Current Deferred Revenue (2024 - 2025)

Nuvation Bio (NUVB) has disclosed Current Deferred Revenue for 2 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 32.4% to $7.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a 32.4% decrease, with the full-year FY2025 number at $7.5 million, down 32.4% from a year prior.
  • Current Deferred Revenue was $7.5 million for Q4 2025 at Nuvation Bio, up from $6.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $12.9 million in Q3 2024 to a low of $6.7 million in Q3 2025.